海南地区静脉血栓栓塞症患者活化蛋白C抵抗与凝血因子V基因多态性研究

陈浩; 肖占祥; 戚悠飞; 曾昭凡; 岳劼; 刘飒华; 李振振; 吴鸿飞; 张文波

doi:10.16016/j.1000-5404.201804140

您当前的位置：

首页 >

文章列表页 >

海南地区静脉血栓栓塞症患者活化蛋白C抵抗与凝血因子V基因多态性研究

临床医学 | 更新时间：2026-01-09

- 海南地区静脉血栓栓塞症患者活化蛋白C抵抗与凝血因子V基因多态性研究
- Activated protein C resistance and genetic polymorphisms of factor V in patients with venous thromboembolism in Hainan Province
- 第三军医大学学报 2018年40卷第20期页码：1894-1897
- 作者机构：
  
  570311 海口, 海南省人民医院血管外科
- 作者简介：
  
  [肖占祥，电话：(0898)68642504, E-mail：xiaozxhn@163.com XIAO Zhanxiang, Tel: 86-898-68642504, E-mail: xiaozxhn@163.com
- 基金信息：
  
  海南省自然科学基金(814317)
- DOI：10.16016/j.1000-5404.201804140
  中图分类号： R195.4;R394.5;R543.6
- 收稿：2018-04-20，
  
  修回：2018-06-25，
  
  纸质出版：2018-10-30
- 稿件说明：
移动端阅览
陈浩, 肖占祥, 戚悠飞, 等. 海南地区静脉血栓栓塞症患者活化蛋白C抵抗与凝血因子V基因多态性研究[J]. 第三军医大学学报, 2018,40(20):1894-1897.

Hao CHEN, Zhanxiang XIAO, Youfei QI, et al. Activated protein C resistance and genetic polymorphisms of factor V in patients with venous thromboembolism in Hainan Province[J]. Journal of Third Military Medical University, 2018, 40(20): 1894-1897.
陈浩, 肖占祥, 戚悠飞, 等. 海南地区静脉血栓栓塞症患者活化蛋白C抵抗与凝血因子V基因多态性研究[J]. 第三军医大学学报, 2018,40(20):1894-1897. DOI： 10.16016/j.1000-5404.201804140.

Hao CHEN, Zhanxiang XIAO, Youfei QI, et al. Activated protein C resistance and genetic polymorphisms of factor V in patients with venous thromboembolism in Hainan Province[J]. Journal of Third Military Medical University, 2018, 40(20): 1894-1897. DOI： 10.16016/j.1000-5404.201804140.

摘要

目的

了解海南地区静脉血栓栓塞症(venous thromboembolism

VTE)患者及健康人群活化蛋白C抵抗(activated protein C resistance

APCR)情况以及可能的凝血因子V基因缺陷(FV Leiden、FV HongKong/Cambridge)。

方法

收集2014年1月至2017年1月在海南省人民医院住院的海南籍汉族VTE患者共计101名以及海南籍健康人群104名，检测两组人群中是否存在APCR现象，用多聚酶链反应-限制性内切酶长度多态性分析(PCR-RLFP)以及基因测序方法检测FV Leiden、FV HongKong/Cambridge基因。

结果

VTE组APCR阳性率明显高于对照组(

0.05)。在101名VTE患者当中检出1例杂合突变FV Leiden和3例FV HongKong基因型，未发现纯合突变FV Leiden以及FV Cambridge基因型。对照组人群中未发现上述异常基因。

结论

APCR可能是导致海南地区人群VTE发病的危险因素，FV Leiden基因在海南人群中少见，FV HongKong可能是海南地区VTE人群较特异的致病基因。

Abstract

Objective

To explore the prevalence of activated protein

resistance (APCR) and accompanying factor V gene defects (FV Leiden

FV HongKong

and FV Cambridge) in patients with venous thromboembolism (VTE) and healthy adults in Hainan Province of China.

Methods

This study was conducted among 101 patients with VTE and 104 healthy adults of Han Nationality from Hainan Province

who were admitted in our hospital between January

2014 and January

2017. Blood samples were obtained from the participants for testing of APCR

and factor V gene mutations (FV Leiden

FV HongKong

and FV Cambridge) were detected using PCR-restriction fragment length polymorphism (PCR-RLFP) and gene sequencing.

Results

The patients with VTE had a significantly higher rate of APCR than the control subjects (

0.05). Of the 101 patients with VTE

1 patient was identified as a factor V Leiden heterozygote carrier and 3 patients were found to carry FV HongKong mutation

while no mutations in factor V gene were found in the control group.

Conclusions

APCR might serve as a risk factor for VTE in the population in Hainan Province

in whom carriers of FV Leiden gene are scarce. FV HongKong may be a specific mutation in the local residents with VTE in Hainan Province.

关键词

Keywords

references

HEIT J A. Epidemiology of venous thromboembolism[J]. Nat Rev Cardiol, 2015, 12(8): 464-474. DOI: 10.1038/nrcardio.2015.83.

BARHOOVER M A, KALAFATIS M. Cleavage at both Arg 306 and Arg 506 is required and sufficient for timely and efficient inactivation of factor Va by activated protein C[J ] . Blood Coagul Fibrinolysis, 2011, 22(4): 317-324. DOI: 10.1097/MBC.0b013e3283456c4e..

方碧晴, 张纪蔚.遗传性静脉血栓栓塞症的研究进展[J].中国血管外科杂志(电子版), 2014, 6(1): 12-15.

FANG B Q, ZHANG J W. Research progress of hereditary venous thromboembolism [J]. Chin J Vase Surg(Electr Vers), 2014, 6(1): 12-15.

CROUS-BOU M, HARRINGTON L B, KABRHEL C. Environmental and genetic risk factors associated with venous thromboembolism[J]. Semin Thromb Hemost, 2016, 42(8): 808-820.

CAMPELLO E, SPIEZIA L, SIMIONI P. Diagnosis and management of factor V Leiden[J]. Expert Rev Hematol, 2016, 9(12): 1139-1149. DOI: 10.1080/17474086.2016.1249364.

CLARK J S, ADLER G, SALKIC N N, et al. Allele frequency distribution of 1691G>A F5 (which confers Factor V Leiden) across Europe, including Slavic populations[J]. J Appl Genet, 2013, 54(4): 441-446. DOI: 10.1007/s13353-013-0166-9.

JUSIĆ-KARIĆ A, TERZIĆ R, JERKIĆ Z, et al. Frequency and association of 1691 (G>A) FVL, 20210 (G>A) PT and 677 (C>T) MTHFR with deep vein thrombosis in the population of Bosnia and Herzegovina[J]. Balkan J Med Genet, 2016, 19(1): 43-50. DOI: 10.1515/bjmg-2016-0006.

ABDI A A, OSMAN A. Prevalence of common hereditary risk factors for thrombophilia in Somalia and identification of a novel Gln544Arg mutation in coagulation factor V[J]. J Thromb Thrombolysis, 2017, 44(4): 536-543. DOI:10.1007/s11239-017-1543-8.

HOSSEINI S, KALANTAR E, HOSSEINI M S, et al. Genetic risk factors in patients with deep venous thrombosis, a retrospective case control study on Iranian population[J]. Thromb J, 2015, 13: 35. DOI: 10.1186/s12959-015-0064-y.

SAEED A, SUMREEN, KASHIF M A. To determine the frequency of Factor V Leiden in cases of deep vein thrombosis and healthy controls[J]. Pak J Med Sci, 2015, 31(5): 1219-1222. DOI: 10.12669/pjms.315.8088.

KUMAR A, MISRA S, SAGAr R, et al. Relationship between Factor V Leiden gene variant and risk of ischemic stroke: a case-control study[J]. Ann Indian Acad Neurol, 2017, 20(3): 284-288. DOI: 10.4103/aian.AIAN_31_17.

SUETA D, ITO M, UCHIBA M, et al. A case of pulmonary thromboembolism due to coagulation factor V Leiden in Japan-usefulness of next generation sequencing[J]. Thromb J, 2017, 15: 8. DOI: 10.1186/s12959-017-0132-6.

KIM S, SONG I, KIM H K, et al. Thrombophilia in Korean patients with arterial or venous thromboembolisms[J]. Ann Surg Treat Res, 2016, 90(6): 340-345. DOI: 10.4174/astr.2016.90.6.340.

张金辉, 冯曜宇, 金辉.静脉血栓栓塞患者携带LeidenV因子杂合子病例报告[J].中国血管外科杂志(电子版), 2014, 6(3): 170-174.

ZHANG J H, FENG Y Y, JIN H. Research of patient with venous thromboembolism carrying Factor V Leiden[J]. Chin J Vase Surg(Electr Vers), 2014, 6(3): 170-174.

褚国芳, 赵凤芹, 石少敏.临床高危因素及凝血酶原基因G20210A突变和FVL突变对肺栓塞的诊断预测价值[J].中国老年学杂志, 2016, 36(5): 1136-1139. DOI: 10.3969/j.issn.1005-9202.2016.05.053.

CHU G F, ZHAO F Q, SHI S M. Clinical risk factors and prognostic value of prothrombin gene G20210A mutation and FVL mutation in pulmonary embolism[J]. Chin J Gerontol, 2016, 36(5): 1136-1139. DOI: 10.3969/j.issn.1005-9202.2016.05.053.

高丽霞, 丁秋兰, 吴克雄, 等.血栓及血栓前状态与凝血因子V基因多态性和APCR及HHcy的相关性研究[J].中国实验血液学杂志, 2016, 24(6): 1850-1855.

GAO L X, DING Q L, WU K X, et al. Correlation of Thrombosis and Prothrombotic State with Coagulation Factor V Gene Polymorphism and APCR.HHcy [J]. J Exp Hematol, 2016, 24(6): 1850-1855.

SHARMA A, BHAKUNI T, BISWAS A, et al. Prevalence of Factor V genetic variants associated with Indian APCR contributing to thrombotic risk[J]. Clin Appl Thromb Hemost, 2017, 23(6): 596-600. DOI: 10.1177/10760296 15623376.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

成年烧伤患者静脉血栓栓塞症风险评估量表的编制及信效度检验

绝经期非肿瘤女性发生静脉血栓栓塞症的危险因素分析及预测模型构建